Cullinan Net Tangible Assets vs Accounts Payable Analysis

CGEM Stock

USD 12.22 0.36 2.86%

Cullinan Oncology financial indicator trend analysis is way more than just evaluating Cullinan Oncology LLC prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cullinan Oncology LLC is a good investment. Please check the relationship between Cullinan Oncology Net Tangible Assets and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

Net Tangible Assets vs Accounts Payable

Net Tangible Assets vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cullinan Oncology LLC Net Tangible Assets account and Accounts Payable. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Cullinan Oncology's Net Tangible Assets and Accounts Payable is 0.18. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Cullinan Oncology LLC, assuming nothing else is changed. The correlation between historical values of Cullinan Oncology's Net Tangible Assets and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Cullinan Oncology LLC are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Net Tangible Assets i.e., Cullinan Oncology's Net Tangible Assets and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.18

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Accounts Payable

An accounting item on the balance sheet that represents Cullinan Oncology obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Cullinan Oncology LLC are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Cullinan Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cullinan Oncology LLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

As of the 22nd of November 2024, Selling General Administrative is likely to grow to about 44.6 M, though Tax Provision is likely to grow to (13.4 M).

	2023	2024 (projected)
Non Recurring	183.9K	97.2K
Research Development	148.2M	155.6M

Non Recurring Research Development

Cullinan Oncology fundamental ratios Correlations

	Total Assets	Total Current Liabilities	Other Liab	Accounts Payable	Other Current Assets	Total Liab	Common Stock	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Cash	Other Assets	Long Term Debt	Net Receivables	Short Long Term Debt	Total Current Assets	Short Term Debt	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total
Total Assets		0.95	-0.52	0.48	0.94	0.15	-0.53	0.94	0.93	-0.85	0.81	0.38	-0.62	0.73	-0.64	0.99	0.65	0.9	0.82	-0.75	0.6	0.3	0.98	0.95	0.87	-0.29
Total Current Liabilities	0.95		-0.49	0.52	0.92	0.24	-0.49	0.86	0.9	-0.88	0.61	0.17	-0.59	0.71	-0.61	0.98	0.68	0.97	0.85	-0.53	0.33	0.43	0.89	0.93	0.81	-0.2
Other Liab	-0.52	-0.49		-0.39	-0.47	-0.39	0.66	-0.38	-0.38	0.5	-0.43	-0.26	0.8	-0.74	0.81	-0.52	-0.47	-0.42	-0.33	0.36	-0.27	-0.27	-0.48	-0.42	-0.56	-0.06
Accounts Payable	0.48	0.52	-0.39		0.43	0.83	-0.53	0.19	0.18	-0.5	0.47	0.49	-0.46	0.52	-0.49	0.49	0.39	0.32	0.17	-0.44	0.25	0.94	0.49	0.25	0.67	0.64
Other Current Assets	0.94	0.92	-0.47	0.43		0.1	-0.46	0.9	0.93	-0.96	0.63	0.44	-0.58	0.69	-0.59	0.93	0.65	0.93	0.67	-0.56	0.53	0.25	0.89	0.94	0.8	-0.34
Total Liab	0.15	0.24	-0.39	0.83	0.1		-0.62	-0.2	-0.17	-0.25	0.13	0.19	-0.47	0.52	-0.49	0.2	0.31	0.04	-0.07	-0.08	-0.13	0.86	0.12	-0.09	0.51	0.87
Common Stock	-0.53	-0.49	0.66	-0.53	-0.46	-0.62		-0.31	-0.31	0.53	-0.48	-0.34	0.8	-0.95	0.85	-0.53	-0.75	-0.37	-0.27	0.4	-0.29	-0.38	-0.5	-0.36	-0.67	-0.23
Total Stockholder Equity	0.94	0.86	-0.38	0.19	0.9	-0.2	-0.31		0.99	-0.76	0.75	0.3	-0.45	0.55	-0.46	0.91	0.53	0.89	0.84	-0.7	0.63	-0.01	0.92	0.97	0.68	-0.6
Net Tangible Assets	0.93	0.9	-0.38	0.18	0.93	-0.17	-0.31	0.99		-0.82	0.65	0.22	-0.46	0.57	-0.47	0.93	0.57	0.95	0.85	-0.59	0.51	0.03	0.89	1.0	0.67	-0.58
Retained Earnings	-0.85	-0.88	0.5	-0.5	-0.96	-0.25	0.53	-0.76	-0.82		-0.48	-0.43	0.61	-0.73	0.62	-0.87	-0.72	-0.88	-0.54	0.39	-0.37	-0.36	-0.79	-0.85	-0.78	0.17
Cash	0.81	0.61	-0.43	0.47	0.63	0.13	-0.48	0.75	0.65	-0.48		0.6	-0.5	0.56	-0.53	0.72	0.36	0.5	0.59	-0.99	0.88	0.21	0.86	0.64	0.74	-0.19
Other Assets	0.38	0.17	-0.26	0.49	0.44	0.19	-0.34	0.3	0.22	-0.43	0.6		-0.31	0.32	-0.33	0.25	0.16	0.08	-0.17	-0.61	0.81	0.2	0.43	0.21	0.46	0.06
Long Term Debt	-0.62	-0.59	0.8	-0.46	-0.58	-0.47	0.8	-0.45	-0.46	0.61	-0.5	-0.31		-0.87	1.0	-0.62	-0.52	-0.51	-0.4	0.42	-0.31	-0.33	-0.57	-0.5	-0.67	-0.06
Net Receivables	0.73	0.71	-0.74	0.52	0.69	0.52	-0.95	0.55	0.57	-0.73	0.56	0.32	-0.87		-0.91	0.74	0.78	0.63	0.49	-0.46	0.34	0.37	0.67	0.62	0.78	0.05
Short Long Term Debt	-0.64	-0.61	0.81	-0.49	-0.59	-0.49	0.85	-0.46	-0.47	0.62	-0.53	-0.33	1.0	-0.91		-0.64	-0.57	-0.52	-0.41	0.44	-0.33	-0.34	-0.59	-0.51	-0.7	-0.08
Total Current Assets	0.99	0.98	-0.52	0.49	0.93	0.2	-0.53	0.91	0.93	-0.87	0.72	0.25	-0.62	0.74	-0.64		0.68	0.95	0.86	-0.65	0.46	0.34	0.95	0.96	0.86	-0.26
Short Term Debt	0.65	0.68	-0.47	0.39	0.65	0.31	-0.75	0.53	0.57	-0.72	0.36	0.16	-0.52	0.78	-0.57	0.68		0.65	0.49	-0.29	0.19	0.26	0.65	0.61	0.63	-0.06
Other Current Liab	0.9	0.97	-0.42	0.32	0.93	0.04	-0.37	0.89	0.95	-0.88	0.5	0.08	-0.51	0.63	-0.52	0.95	0.65		0.85	-0.41	0.27	0.24	0.84	0.97	0.71	-0.38
Property Plant And Equipment Net	0.82	0.85	-0.33	0.17	0.67	-0.07	-0.27	0.84	0.85	-0.54	0.59	-0.17	-0.4	0.49	-0.41	0.86	0.49	0.85		-0.54	0.27	0.12	0.79	0.86	0.59	-0.43
Net Debt	-0.75	-0.53	0.36	-0.44	-0.56	-0.08	0.4	-0.7	-0.59	0.39	-0.99	-0.61	0.42	-0.46	0.44	-0.65	-0.29	-0.41	-0.54		-0.9	-0.17	-0.82	-0.58	-0.68	0.19
Non Current Assets Total	0.6	0.33	-0.27	0.25	0.53	-0.13	-0.29	0.63	0.51	-0.37	0.88	0.81	-0.31	0.34	-0.33	0.46	0.19	0.27	0.27	-0.9		-0.08	0.68	0.48	0.52	-0.34
Non Currrent Assets Other	0.3	0.43	-0.27	0.94	0.25	0.86	-0.38	-0.01	0.03	-0.36	0.21	0.2	-0.33	0.37	-0.34	0.34	0.26	0.24	0.12	-0.17	-0.08		0.27	0.1	0.48	0.74
Cash And Short Term Investments	0.98	0.89	-0.48	0.49	0.89	0.12	-0.5	0.92	0.89	-0.79	0.86	0.43	-0.57	0.67	-0.59	0.95	0.65	0.84	0.79	-0.82	0.68	0.27		0.9	0.85	-0.29
Common Stock Total Equity	0.95	0.93	-0.42	0.25	0.94	-0.09	-0.36	0.97	1.0	-0.85	0.64	0.21	-0.5	0.62	-0.51	0.96	0.61	0.97	0.86	-0.58	0.48	0.1	0.9		0.71	-0.52
Common Stock Shares Outstanding	0.87	0.81	-0.56	0.67	0.8	0.51	-0.67	0.68	0.67	-0.78	0.74	0.46	-0.67	0.78	-0.7	0.86	0.63	0.71	0.59	-0.68	0.52	0.48	0.85	0.71		0.12
Non Current Liabilities Total	-0.29	-0.2	-0.06	0.64	-0.34	0.87	-0.23	-0.6	-0.58	0.17	-0.19	0.06	-0.06	0.05	-0.08	-0.26	-0.06	-0.38	-0.43	0.19	-0.34	0.74	-0.29	-0.52	0.12

Click cells to compare fundamentals

Cullinan Oncology Account Relationship Matchups

Cullinan Oncology fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	100.5M	214.7M	437.2M	561.1M	484.2M	508.4M
Total Current Liabilities	2.5M	14.3M	11.7M	22.5M	28.1M	29.5M
Accounts Payable	934K	9.7M	3.2M	2.7M	2.5M	2.0M
Other Current Assets	1.5M	4.1M	12.2M	7.2M	13.1M	13.8M
Total Liab	140.4M	291.0M	11.8M	26.1M	30.3M	55.9M
Total Stockholder Equity	(40.8M)	(77.6M)	422.6M	535.0M	453.7M	476.4M
Net Tangible Assets	(40.8M)	(77.6M)	425.0M	535.0M	615.3M	646.0M
Retained Earnings	(41.5M)	(93.3M)	(158.9M)	(47.7M)	(200.9M)	(190.8M)
Cash	63.3M	168.2M	430.9M	550.1M	98.4M	147.9M
Total Current Assets	100.1M	212.3M	296.6M	474.5M	480.2M	504.2M
Other Current Liab	1.6M	4.6M	8.6M	14.0M	22.8M	23.9M
Property Plant And Equipment Net	182K	130K	77K	5.3M	3.5M	3.7M
Net Debt	(63.3M)	(168.2M)	(430.9M)	(544.9M)	(94.8M)	(99.6M)
Non Current Assets Total	370K	2.4M	140.6M	86.6M	4.0M	3.8M
Cash And Short Term Investments	98.6M	210.2M	430.9M	550.1M	467.1M	328.3M
Short Term Investments	35.4M	42.0M	230.7M	311.1M	368.6M	387.1M
Liabilities And Stockholders Equity	100.5M	214.7M	434.8M	561.1M	484.2M	335.5M
Non Current Liabilities Total	137.8M	276.7M	65K	3.6M	2.2M	2.0M
Other Stockholder Equity	(137.0M)	15.7M	584.7M	585.3M	654.7M	687.4M
Net Invested Capital	(40.8M)	(77.6M)	425.0M	535.2M	453.7M	233.7M
Property Plant And Equipment Gross	182K	130K	309K	5.4M	3.9M	4.1M
Accumulated Other Comprehensive Income	(4K)	(2K)	(838K)	(2.6M)	(129K)	(135.5K)
Net Working Capital	97.6M	198.0M	284.8M	452.0M	452.1M	278.2M
Property Plant Equipment	182K	130K	77K	1.2M	1.4M	1.4M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Cullinan Oncology LLC is a strong investment it is important to analyze Cullinan Oncology's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cullinan Oncology's future performance. For an informed investment choice regarding Cullinan Stock, refer to the following important reports:

How To Invest In Cullinan

Details

Is Cullinan Stock a good investment?

Details

What is Cullinan Oncology's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cullinan Oncology LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.

You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.84)

Return On Assets

(0.20)

Return On Equity

(0.27)

The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cullinan Net Tangible Assets vs Accounts Payable Analysis

Net Tangible Assets vs Accounts Payable

Net Tangible Assets vs Accounts Payable Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Accounts Payable

Cullinan Oncology fundamental ratios Correlations

Cullinan Oncology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cullinan Oncology fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock Total Equity	+ 1.0	Net Tangible Assets
Short Long Term Debt	+ 1.0	Long Term Debt
Total Current Assets	+ 0.99	Total Assets
Net Tangible Assets	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.98	Total Assets
Total Current Assets	+ 0.98	Total Current Liabilities

Net Debt	- 0.99	Cash
Retained Earnings	- 0.96	Other Current Assets
Net Receivables	- 0.95	Common Stock
Short Long Term Debt	- 0.91	Net Receivables
Non Current Assets Total	- 0.9	Net Debt
Other Current Liab	- 0.88	Retained Earnings